However, investigating the viral infection enhancing activity of this HuMAb on Fc-gamma receptor (FcγR)-bearing cells revealed an increase in DENV infection at sub-neutralizing concentrations, which limits its application as a therapeutic candidate (Sasaki et al., 2013). Here, FCGR2A is linked to viral infectious disease.